Onzima Ventures Plc Investment Update and Change of Registered Office

 
TIDMONZ 
 
Onzima Ventures plc 
 
                          ("Onzima" or the "Company") 
 
    Investee company N4 Pharma announces latest research results for Nuvec® 
 
                          Change of registered office 
 
N4 Pharma Limited ("N4 Pharma"), in which Onzima holds a 49% equity stake, has 
announced that it has successfully demonstrated in-vitro transfection 
efficiency for its Nuvec® DNA vaccine system comparable to industry standard 
transfection reagents. 
 
Its latest results show that optimised Nuvec® particles achieved 80-90% 
transfection efficiency in HEK 293 cells, the same levels as Lipofectamine 
2000. 
 
These results can be found here: http://www.n4pharma.co.uk/download/i/mark_dl/u 
/4013008883/4630405716/nuvec%20dna%20transfection%20results%201.pdf 
 
N4 Pharma CEO Nigel Theobald commented: 
 
"Our research on our Nuvec® particles continues to show impressive results. 
Lipofectamine is widely used for DNA transfection experiments as it achieves 
high levels of in-vitro transfection efficiency however it has been 
demonstrated to have negative toxic effects on cells so is not used in 
commercial product development for in-vivo administration. 
 
We are continuing to build our evidence on Nuvec towards establishing its 
acceptability as an in-vivo delivery vector for DNA and RNA based vaccines. Our 
next steps are to compare the  toxicity of Nuvec® with lipofectamine® where we 
expect to show markedly lower toxicity of our particles making them more 
suitable for in-vivo use. 
 
We are clearly able to demonstrate high transfection levels, which opens up the 
potential for longer term use of Nuvec® as an in-vivo transfection agent for 
DNA vaccines. Our R&D program is designed step by step to build the supporting 
case for this application for the  nuvec® system. 
 
This latest data represents strong steady progress on the path towards 
commercialisation of Nuvec®. We expect further results comparing  the toxicity 
and transfection efficiency of Nuvec® against  a wider range of existing 
transfection agents in a range of  different cell types, over the next 3 or 4 
months including comparison against those vectors already established for 
in-vivo use. " 
 
The Company also announces that its registered office has now changed to 6th 
Floor, 60 Gracechurch Street, London EC3V 0HR. 
 
For further information please contact: 
 
Onzima Ventures PLC                Tel:  [phone] 
Gavin Burnell, Luke Cairns 
 
Nominated Adviser 
Cairn Financial Advisers LLP              Tel:  [phone] 
Sandy Jamieson, Liam Murray 
 
Broker 
Peterhouse Corporate Finance Limited        Tel:  [phone] 
Guy Miller, Lucy Williams 
 
 
 
END 
 

(END) Dow Jones Newswires

November 11, 2016 09:16 ET (14:16 GMT)